This Practice Note provides practical guidance on the World Trade Organization’s (WTO) Agreement on Trade in Pharmaceutical Products (the Pharma Agreement).
Introduction
During the Uruguay Round in 1994, some WTO Member States agreed to a plurilateral agreement on pharmaceutical products, namely the Pharma Agreement. The Member States party to the Pharma Agreement agreed to eliminate and/or reduce tariffs on specific sectors. These commitments only apply among the Member States that are a party to the Pharma Agreement. As such, only those Member States may rely on the Most Favoured Nation (MFN) principle. For guidance on the MFN principle, see Practice Note: An introduction to Trade in Goods.
Which Member States are part of the Pharma Agreement
Currently, the following Member States are party to the Pharma Agreement:
- •
Canada
- •
The EU
- •
Japan
- •
Macao (China)
- •
Norway
- •
Switzerland
- •
The UK, and
- •
The USA
The Pharma Agreement also lists Australia as a party, however, Australia did not agree to be included in the list of Member States that concluded the Pharma Agreement
To view the latest version of this document and thousands of others like it,
sign-in with LexisNexis or register for a free trial.